Improving Stroke Motor Control With Non-invasive Brain Stimulation and Functional Electrical Stimulation
Launched by METROHEALTH MEDICAL CENTER · Feb 26, 2019
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring new ways to help stroke patients regain control of their hands after experiencing weakness on one side of their body, a condition known as hemiplegia. The study will test a combination of two treatments: non-invasive brain stimulation, which gently stimulates the brain, and functional electrical stimulation, which uses small electrical pulses to help muscles move. By carefully timing and delivering these treatments, researchers hope to improve hand movement and brain activity related to motor control.
To participate in this study, individuals need to be at least 21 years old and have had their first stroke at least six months ago. Also, they should be able to follow simple commands and have some movement in their unaffected arm. Participants will need to sit comfortably during the sessions and must not have any other significant neurological conditions. If someone meets these criteria, they can expect to engage in exercises designed to improve their hand function, while also receiving these innovative treatments. This trial is currently recruiting participants, and the goal is to find effective rehabilitation methods for stroke survivors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 21
- • 2. ≥ 6 months since first clinical hemorrhagic or nonhemorrhagic stroke
- • 3. Able to follow 3-stage commands and remember 2 of 3 items after 30 minutes
- • 4. Full volitional elbow extension/flexion and hand opening/closing of unaffected limb
- • 5. Adequate active movement of shoulder and elbow to position the paretic hand in the workspace for table-top task practice
- • 6. Patient must be able to sit unassisted in an armless straight-back chair for the duration of the screening portion of the eligibility assessment
- • 7. Medically stable
- • 8. ≥ 10° finger extension
- • 9. Unilateral upper limb hemiparesis with finger extensor strength of ≤ grade 4/5 on the manual muscle test AND a score of
- • ≥1 and ≤ 11/14 on the hand section of the upper extremity Fugl-Meyer Assessment
- • 10. Skin intact on hemiparetic arm, hand and scalp
- • 11. While relaxed, surface neuromuscular electrical stimulation of finger extensors and thumb extensors and/or abductors produces a functional degree of hand opening without pain.
- • 12. No significant visual or hearing impairment
- Exclusion Criteria:
- • 1. Co-existing neurological condition other than prior stroke involving the hemiparetic upper limb (e.g., peripheral nerve injury, Parkinson's disease, spinal cord injury, traumatic brain injury, multiple sclerosis).
- • 2. Uncontrolled seizure disorder
- • 3. Use of seizure lowering threshold medications at the discretion of the study physician (Dr. Rich Wilson)
- • 4. Cardiac pacemaker or other implanted electronic device and/or stent
- • 5. Pregnant
- • 6. Intramuscular botox injections in any upper extremity muscle in the last 3 months
- • 7. Insensate arm, forearm, or hand
- • 8. Severely impaired cognition and communication
- • 9. Uncompensated hemi-neglect (extinguishing to double simultaneous stimulation)
- • 10. Severe shoulder or hand pain (unable to position hand in the workspace without pain)
- • 11. Metal implant in the head
About Metrohealth Medical Center
MetroHealth Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor, MetroHealth collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. With a commitment to ethical research practices and participant safety, the center leverages its extensive resources and expertise to contribute to the scientific community and enhance healthcare outcomes. Through rigorous clinical trials, MetroHealth aims to translate research findings into tangible benefits for patients, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Patients applied
Trial Officials
David A Cunningham, PhD
Principal Investigator
MetroHealth Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials